SAN DIEGO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced its 2024 Symposium, the quintessential event for the optical genome mapping (OGM) community. The event is an opportunity for OGM users to present their progress to the world. 2024 Symposium will feature four consecutive days of OGM presentations delivered by 27 different customers worldwide across a wide range of applications in cancer, cell and gene therapy, and constitutional genetic disease. The Symposium wi ...

SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO), today announced a publication outlining the addition of optical genome mapping (OGM) to the International System for Human Cytogenomic Nomenclature (ISCN). The OGM nomenclature is expected to be published in the 2024 edition of the ISCN guide, a reference volume covering ISCN nomenclature that is utilized worldwide by cytogeneticists, molecular biologists, technicians, and students. ISCN nomenclature is an international stand ...

SAN DIEGO, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO), today announced significant upgrades to its pipeline for analysis of optical genome mapping (OGM) data in its VIA™ software for applications in constitutional genetic disease. The latest analysis pipeline, Bionano Solve 3.8.1, enhances the sensitivity and specificity for structural variation (SV) detection from OGM data, which, when combined with copy number variant (CNV) analysis capabilities introduced in July 2023, further ...

Key findings from prospective evaluation of 200 prenatal samples: Optical genome mapping (OGM) detected pathogenic structural variants (SVs) in 20.5% of samples (41/200); combination of chromosomal microarray analysis (CMA) and karyotyping (KT) detected pathogenic SVs in 19.5% of samples (39/200)Compared to CMA and KT combined in this prospective cohort, OGM had the following performance: Sensitivity: 97.4%Specificity: 100%Positive Predictive Value (PPV): 100%Negative Predictive Value (NPV): 99.4% For 8 co ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Stifel Healthcare Conference Call November 15, 2023 1:50 PM ET Company Participants Erik Holmlin - CEO Conference Call Participants Dan Arias - Stifel Dan Arias Okay. Welcome back to the 2023 Stifel Healthcare Conference Day Two. We are on the life sciences and diagnostics track here. I am Dan Arias. I’m the life sciences and diagnostics analyst. We’re happy to have with us our next company, Bionano Genomics. CEO, Erik Holmlin is with us. I think, Erik, maybe you’re goin ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants David Holmes - Investor Relations Erik Holmlin - Chief Executive Officer Gülsen Kama - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Sung Ji Nam - Scotiabank Jeffrey Cohen - Ladenburg Thalmann Operator Good day, and welcome to the Bionano's Third Quarter 2023 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38613 _________________________________________________________ Bionano Genomics, Inc. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Canaccord Genuity 43rd Annual Growth Conference August 10, 2023 11:30 AM ET Company Participants Erik Holmlin - President and Chief Executive Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Kyle Mikson Welcome to the Canaccord Genuity Global Growth Conference. I'm Kyle Mikson of Life Science Tools and Diagnostics for Canaccord. Pleased to have Bionano Genomics here. Bionano offers one of the leading platforms for optical genome mapping. With us from ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO Chris Stewart - CFO Conference Call Participants Jason McCarthy - Maxim Group Mark Massaro - BTIG Sung Ji Nam - Scotiabank Daniel Hultberg - Oppenheimer Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Bionano's Second Quarter 2023 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the c ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and ''emerging growth company'' in Rule 12b-2 of the Exchange Act. Indicate by check mark whether regist ...